Draft. Pending scientific and legal review. Not medical advice.
BrainGenomarkers · Psychiatry
BrainGenomarkers · Psychiatry brings together genetic susceptibility panels for psychiatric disorders, including depression and schizophrenia. They list variants associated with complex traits. They do not establish a diagnosis or predict individual clinical course. Interpretation belongs to qualified staff.
Scope
The catalogue lists broad-coverage NGS panels for depression and schizophrenia. They are framed as risk or susceptibility panels, not as diagnostic tests for a psychiatric disorder.
The genetics of common mental disorders is polygenic, with modest effect per variant. A list of associated variants is not a clinical diagnosis and not an individual prognosis.
Relation to pharmacogenomics
In practice, the genetic question in psychiatry may concern susceptibility or response to psychotropic medicines. Pharmacogenomics (ADME genes and targets) is described in its own area and draws on CPIC and DPWG guidelines when gene-drug pairs have sufficient evidence.
This area page does not recommend medicines or doses. Any therapeutic adjustment requires medical supervision.
Limits
Per the catalogue notice on complex traits: associated variants are listed; an individual predictive value is not established. Results must be placed in the clinical history, environment and specialist judgement.
Pending Phase 0: sample, turnaround, sensitivity and a sample report. Also confirmation of the name «BrainGenomarkers · Psychiatry».
